News Conference News ESC 2025 High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors Caitlin E. Cox August 29, 2025
News Conference News ESC 2024 Endometriosis and CV Risk: Link Needs Further Attention and Research Yael L. Maxwell September 12, 2024
News Conference News ESC 2024 Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events Caitlin E. Cox August 31, 2024
News Conference News ESC 2023 STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function Shelley Wood August 25, 2023
News Conference News ESC 2022 COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19 Todd Neale September 01, 2022
News Conference News ESC 2022 Polypill Bests Usual Care in Patients With Recent MI: SECURE Michael O'Riordan August 26, 2022
News Conference News ESC 2020 LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease Caitlin E. Cox August 31, 2020
News Conference News ESC 2018 MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis Todd Neale August 26, 2018
Presentation ESC 2017 Anti-Inflammatory Therapy with Canakinumab for Atherosclerotic Disease Presenter: Paul M. Ridker August 27, 2017
News Conference News ESC 2017 CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events Michael O'Riordan August 27, 2017
News Opinion Editor's Corner ESC 2017 ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On Shelley Wood August 18, 2017